Pharmaceuticals

TRT released FY2026 Q1 earnings on April 29 Pre-Market (BJT), actual revenue CNY 4.664 B (forecast CNY 5.091 B), actual EPS CNY 0.344 (forecast CNY 0.35)

TRT to Release FY2026 Q1 Earnings on April 30 Pre-Market (BJT), Forecast Revenue CNY 5.091 B, EPS CNY 0.35

TRT released FY2025 Annual Earnings on March 30 After-Market (BJT), actual revenue CNY 17.26 B (forecast CNY 18.3 B), actual EPS CNY 0.867 (forecast CNY 1.0665)

TRT released FY2025 Q4 earnings on March 30 After-Market (BJT), actual revenue CNY 3.948 B (forecast CNY 4.858 B), actual EPS CNY 0.0085 (forecast CNY 0.31)

TRT to Release FY2025 Earnings on March 31 After-Market (BJT), Forecast Revenue CNY 18.3 B, EPS CNY 1.0665

Tongrentang Subsidiary Suspected of Selling Fake Krill Oil

Alibaba Health and Beijing Tong Ren Tang Partner to Build Holistic Care Loop for Cardiovascular Diseases

TRT released FY2025 Q3 earnings on October 30 After-Market (BJT), actual revenue CNY 3.539 B (forecast CNY 4.162 B), actual EPS CNY 0.1696 (forecast CNY 0.24)

TRT released FY2025 9 Months Earnings on October 30 After-Market BJT, actual revenue CNY 13.31 B, actual EPS CNY 0.8589

TRT to release FY2025 Q3 earnings on October 31 After-Market (BJT), forecast revenue CNY 4.162 B, EPS CNY 0.24

TRT released FY2025 Q2 earnings on August 29 During-Market (BJT), actual revenue CNY 4.493 B (forecast CNY 4.923 B), actual EPS CNY 0.2642 (forecast CNY 0.355)

TRT released FY2025 Semi-Annual Earnings on August 29 During-Market (BJT), actual revenue CNY 9.769 B, actual EPS CNY 0.689

TRT FY2025 Semi-Annual Earning Release on August 30, 2025 (BJT)

Tong Ren Tang's Executive Vice President Zhang Chunyou Resigns Due to Work Adjustment

Beijing Tong Ren Tang Healthcare Again Submits Main Board Listing Application

Tong Ren Tang Plans to Split Off and List Tong Ren Tang Health Care on Hong Kong Exchange

Tong Ren Tang Pharmaceutical Factory's Su He Xiang Pills Obtain Canadian Product Registration

Tong Ren Tang monitors imported bezoar policy without impacting daily operations

Tong Ren Tang Announces 2025 Q1 Financial Report

TRT released FY2025 Q1 earnings on April 29 Pre-Market (BJT), actual revenue CNY 5.276 B (forecast CNY 5.414 B), actual EPS CNY 0.425 (forecast CNY 0.38)

01666

00570

03613

600085

159849

512010

516500

516930

513060

159929

Recently, the National Chinese Herbal Pieces Alliance Procurement Office released centralized procurement documents, proposing to purchase 41 varieties of Chinese herbal pieces, categorized into two specification grades: selected goods and unified goods. This procurement follows the principles of 'stabilizing clinical use, ensuring quality, opposing internal competition, and preventing bid rigging,' led by the Shandong Medical Security Bureau, and is expected to reshape a market valued at 300 billion yuan

Wallstreetcn

TONG REN TANG

TRAD CHI MED

TONGRENTANGCM

CR Sanjiu

E Fund CSI HK Equities Medical and Health Integration ETF

Taikang CNI Public Health and Medical Health ETF

China Merchants CSI Biotechnology Theme ETF

E Fund CSI 300 Health Care ETF

Guotai SSE STAR Brand Name Drug ETF

ChinaAMC CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

Minsheng Royal CSI Biotechnology Theme ETF

Bosera Hang Seng Health Care ETF(QDII)

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

China Universal 800 Health Care ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

GF CSI All Share Health Care ETF

New Progress in Centralized Procurement of Chinese Herbal Pieces: 41 Varieties Included, 300 Billion Market Landscape to Change

TONG REN TANG announced its 2025 annual performance, with revenue of 6.484 billion RMB, a year-on-year decrease of 10.7%. It recorded a net profit of 396 million RMB, down 24.1%, with earnings per share of 31 cents. The final dividend remains at 18 cents

AASTOCKS

In the "Performance" report, TONG REN TANG announced a full-year net profit of 396 million RMB, a decrease of 24.1%, with a final dividend of 18 cents

01079

Tongrentang Medical and Health has urgently halted its listing plan due to market conditions, resulting in only 4 new stocks being listed next Monday. Deshi performed the best, closing up 94.7%, with a paper profit of HKD 4,685 to HKD 5,025 per lot; Huayan Robotics rose 5.4%, with a paper profit of HKD 182 to HKD 354 per lot. Tongrentang Medical and Health has decided to delay its listing and return the application funds, but remains committed to completing the global offering in a timely manner. Fourier and Copper Master will be listed next Tuesday, both priced at the lower limit of their offering price. Jifei Technology has submitted a listing application, expecting to raise USD 200 million

Stheadline

PINE TECH

4 New stocks in the dark market "report success" with DeShi showing double profits, while HuaYan Robotics only rises by 10%

513700

Beijing Tong Ren Tang Healthcare Investment has postponed its Hong Kong IPO, originally scheduled for Monday, due to unfavorable market conditions. The company aimed to raise up to HK$897.7 million by offering 108.15 million shares. Investor demand was weak, with the public tranche only 4.85 times oversubscribed. Retail and institutional investors will receive refunds by March 30. The firm, part of a larger group known for traditional Chinese medicine, had cleared its listing hearing last year but delayed the offer due to market volatility and concerns over post-listing performance.

SCMP

Penghua CSI HK Connect Health Care Composite ETF

Tong Ren Tang healthcare unit pulls Hong Kong IPO scheduled for Monday

Tongrentang Medical Care will open its initial public offering (IPO) on March 23, with plans to list on the Hong Kong Stock Exchange on March 30, 2026, aiming to raise HKD 900 million, with an issuance range of HKD 7.3 to 8.3. Cornerstone investors include Airport Technology Capital and Aurora SF, collectively subscribing for HKD 389 million. In the first nine months of 2025, revenue was HKD 858 million, with a profit decline of 9.7%. Tongrentang Medical Care is a traditional Chinese medicine healthcare group, owning multiple offline and online medical institutions

雷帝触网

Tongrentang Medical and Health has opened its IPO: plans to raise HKD 900 million and list on March 30, with a 10% decline in profits over 9 months

Tong Ren Tang Medical and Health has launched its IPO, planning to raise up to HKD 898 million, with the goal of acquiring and establishing 10 medical institutions by 2029. The company relies on its 300-year-old brand to provide integrated traditional Chinese medicine services, addressing the health management needs arising from China's aging population. The IPO was launched on March 20, with a proposed issuance of 108 million shares, priced between HKD 7.30 and 8.30, and is expected to be listed for trading on March 30

BambooWorks

TRT launches IPO to provide medical and health services relying on its time-honored brand

Tong Ren Tang Medical will conduct an initial public offering from March 20 to 25, planning to issue 110 million H shares, with an offering price ranging from HKD 7.3 to HKD 8.3, aiming to raise nearly HKD 900 million. As of March 23, it has received HKD 250 million in margin subscriptions, oversubscribed by 1.8 times. Each lot consists of 500 shares, with an entry fee of HKD 4,191.9, and it is expected to be listed for trading on March 30. China International Capital Corporation is the sponsor

Tasty Money

【New Stock IPO】【Subscription Situation】【Continuously Updated】Traditional Chinese Medicine Healthcare Service Industry Tong Ren Tang Medical Care (2667) received HKD 250 million in margin financing, with an oversubscription of 1.8 times

Tong Ren Tang Technologies Co. reported a decline in revenue and profit for its subsidiary, Beijing Tong Ren Tang Chinese Medicine Company Limited, for 2025. Revenue fell to HK$1.51 billion from HK$1.61 billion, and profit attributable to owners dropped to HK$397.2 million from HK$500.3 million. The decrease was attributed to reduced gross profit, higher impairment losses, and weaker equity contributions. The subsidiary's gross profit decreased to HK$925.6 million, and basic earnings per share slipped to HK$0.47. Analysts rate the stock as a Hold with a price target of HK$4.50.

Tip Ranks

Tong Ren Tang Subsidiary Posts Lower 2025 Profit as Revenue and Margins Decline

TRT(600085.SH)